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SUMMARY
Basket trials have emerged as a new class of efficient approaches in oncology to evaluate a new treatment
in several patient subgroups simultaneously. In this article, we extend the key ideas to disease areas outside
of oncology, developing a robust Bayesian methodology for randomized, placebo-controlled basket trials
with a continuous endpoint to enable borrowing of information across subtrials with similar treatment
effects.After adjusting for covariates, information from a complementary subtrial can be represented into
a commensurate prior for the parameter that underpins the subtrial under consideration.We propose using
distributional discrepancy to characterize the commensurability between subtrials for appropriate borrow-
ing of information through a spike-and-slab prior, which is placed on the prior precision factor. When the
basket trial has at least three subtrials, commensurate priors for point-to-point borrowing are combined
into a marginal predictive prior, according to the weights transformed from the pairwise discrepancy
measures. In this way, only information from subtrial(s) with the most commensurate treatment effect is
leveraged. The marginal predictive prior is updated to a robust posterior by the contemporary subtrial data
to inform decision making. Operating characteristics of the proposed methodology are evaluated through
simulationsmotivated by a real basket trial in chronic diseases. The proposedmethodology has advantages
compared to other selected Bayesian analysis models, for (i) identifying the most commensurate source
of information and (ii) gauging the degree of borrowing from specific subtrials. Numerical results also
suggest that our methodology can improve the precision of estimates and, potentially, the statistical power
for hypothesis testing.
Keywords: Basket trials; Hellinger distance; Hierarchical models; Precision medicine; Robustness.
1. INTRODUCTION
There has been an increasing interest in precision medicine (Mirnezami and others, 2012; Schork, 2015)
over the past few decades. Rapid advances in genomics and biomarkers allow stratification of patients
into subgroups that may have different benefit from new treatments. Unlike the one-size-fits-all concept in
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conventional paradigms of clinical drug development, the aim of precision medicine is to target the right
treatments to the right patients at the right time. In the era of precision medicine, new trial designs have
been developed, several ofwhich are examples ofmaster protocols (Woodcock andLaVange, 2017; Renfro
and Mandrekar, 2018) to study multiple diseases or multiple agents, or sometimes both. One well-known
class of master protocols is basket trials (Renfro and Sargent, 2017). In the simplest formulation, basket
trials evaluate a single-targeted agent to patients that share a common feature, such as similar genetic
mutation, but may present various disease subtypes. It is administratively more efficient to plan a basket
trial than a number of separate trials for the small subgroups, respectively. With one subtrial performed
in each patient subgroup, basket trials are advantageous also for addressing multiple research questions
simultaneously, for example, which subgroup(s) of patients may benefit and to what extent. To date,
sophisticated approaches to the design and analysis of basket trials have predominantly been proposed for
early phase oncology drug development, where the “standard” approach is a single-arm design with binary
RECIST endpoint (Eisenhauer and others, 2009; Schwartz and others, 2016). This manuscript extends
the key ideas of basket trials to disease areas outside of oncology, for example, in cases where patients
have distinct clinical conditions but share similar symptoms. For this, we develop efficient approaches for
analyzing randomized, placebo-controlled basket trials which collect data on a continuous endpoint.
When analyzing early phase basket trials, one major concern is the potential heterogeneity of the
treatment effect in various patient subgroups. Investigators are faced with the dilemma of discarding
or incorporating data from other subgroups to reach a decisive conclusion about the treatment effect
for a specific subgroup. The option of using complementary data from subtrials that run concurrently is
intriguing, as it may lead to considerable increase in the statistical power of the study to detect drug activity
in one ormore subgroups. This should be balancedwith the risk that treatment effect in an important patient
subgroup may be overlooked or missed. Conventional analysis strategies such as stand-alone analyses
(also known as the approach of no borrowing) and complete pooling irrespective of subgroup labels have
been criticized. Some authors have proposed using hierarchical random-effects models, as a compromise
between the two limiting opinions, to enable borrowing of information across subgroups (Thall and others,
2003; Thall andWathen, 2008; Berry and others, 2013). Such well-established approaches for information
borrowing are justified, under the assumption of the exchangeability (Bernardo, 1996) of subgroup-specific
treatment effects. More specifically, exchangeability means that the magnitude of clinical benefit may
differ, but nothing is known a priori to suppose patients of some subgroups benefit better than others.
Neuenschwander and others (2016) discuss a robust extension to the standard hierarchical models by
including the possibility of non-exchangeability for each parameter (vector) that underpins a subgroup.
Their approach permits an extreme subgroup not to be overly influenced by other subgroups in situations
of data inconsistency.
Additional concerns about the subgroup effect are essential in precision medicine. Often, the targeted
therapy is effective only in some subgroups, and certain subgroups illustrate more similar clinical benefit
between themselves than with others. Several variations of standard hierarchical modeling have been
considered suitably for the context of basket trials to implement borrowing of information (Liu and oth-
ers, 2017; Chu and Yuan, 2018). Modifications are motivated mainly by (i) justification about plausible
clustering of similar subgroups and (ii) quantification about the magnitude, to which a subgroup-specific
parameter should be shrunk towards the mean effect across subgroups. Most recently, more sophisticated
methods in the framework of Bayesian model averaging (Madigan and Raftery, 1994; Draper, 1995) have
been applied to analyzing basket trials. Psioda and others (2019) average over the complete model space,
which is constituted by all models for possible configurations of the subgroups that may demonstrate
the same or disparate efficacy. In a model that assumes identical treatment effect among specific sub-
groups, information is pooled across the corresponding subgroups under the assumption of inter-patient
exchangeability. The number ofmodels to be included in the completemodel space for averaging increases
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exponentially with the number of subgroups involved in the basket trial. Hobbs and Landin (2018) enu-
merate all possible subgroup pairs, wherein the parameters are considered to be either exchangeable or
non-exchangeable. Using the product of, rather than the individual, prior probabilities for any two sub-
groups being exchangeable or not, their method offers considerable computational efficiency with respect
to conventional Bayesian model averaging.
In this article, we propose methodology motivated by a randomized, placebo-controlled phase II basket
trial, which is being undertaken in patients with chronic diseases. Patients who share a common disease
symptom that the new treatment can potentially improve, will be stratified into subgroups according to
their clinical conditions. Efficacy will be recorded on a continuous endpoint. Adjustment for baseline
covariate(s) is desirable to allow for a more precise estimate of treatment effect. We develop a Bayesian
methodology for borrowing of information across consistent subgroups based on commensurate priors
(Hobbs and others, 2011, 2012), which lead to a type of hierarchical model for robust estimation in
circumstances of just a small number of complementary studies. Using it can facilitate inferences with
respect to all possible pairwise borrowing of information between K subgroups in a basket trial, which
accounts for the level of data commensurability across subtrials.More explicitly, given any complementary
subtrial data, a commensurate prior can be specified for the treatment effect in the subtrial of contemporary
analysis interest. It is basically a normal predictive prior centered at the complementary subtrial data
parameter, with a precision factor to capture the commensurability of the parameters that underpin the
complementary and contemparory subtrials.
We explore placing an empirical spike-and-slab prior (Mitchell and Beauchamp, 1988) on the precision
factor, which determines the degree of point-to-point borrowing. For overcoming a prior-data conflict, we
propose using a distributional discrepancy measure to characterize the commensurability of information
between any two subtrials. It could quantify the probabilitymass to be placed on the “spike” prior for strong
borrowing, and that on the “slab” prior for discounting inconsistent information from a complementary
subtrial, respectively. This discrepancy measure meanwhile discerns the complementary subtrials (when
at least three subgroups are involved) according to their relative commensurability, and can therefore
encourage differential borrowing of information to estimate the model parameter specific to a subtrial.
The proposed methodology for basket trials is fundamentally different from the existing approaches to
information sharing. It avoids the limiting assumption about exchangeability for parameters of certain
or all subtrials but features the use of a distributional discrepancy measure to inform the borrowing only
from the most commensurate subtrial(s).
The remainder of this article is structured as follows.We describe the motivating example and decision
criteria in Section 2. In Section 3, we present our analysis methodology and discuss how a discrepancy
measure may help make appropriate use of complementary data in a basket trial. In Section 4, we perform
a simulation study to evaluate the operating characteristics of phase II basket trials that would have
been analyzed using the proposed methodology, and compare our Bayesian model with some alternative
analysis models. We close with a discussion of our findings and future research that arises in Section 5.
2. MOTIVATING EXAMPLE AND NOTATION
We use a randomized, placebo-controlled phase II basket trial, as a motivating example, which evaluates a
new treatment for cognitive dysfunction in patients of primary biliary cholangitis (PBC) and Parkinson’s
disease (PD). This clinical trial is led by Newcastle University; at the time of writing, it has been funded
but not yet opened to participants. By stages and types of the chronic diseases, patients are to be recruited
and stratified into three disjoint subgroups, that is, early-stage PBC, late-stage PBC, and PD. The PBC and
PD basket trial thus comprises three subtrials. A continuous outcome measuring cognitive performance
will be used as the clinical endpoint in each subtrial. Once the trial begins, patients within each subtrial
will be randomized to receive either the new treatment or a placebo.
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For each subtrial k = 1, . . . ,K , we suppose nk patients are to be recruited. The binary indicator with
respect to the treatment assignment is denoted by Tik for patient i = 1, . . . , nk . Specifically, Tik = 1 if
patient i in subtrial k is allocated to the treatment and 0 if a placebo. From each patient, data are measured
on covariates, denoted by zik = {zik1, . . . , zikq}, and a post-treatment outcome of clinical interest, denoted
by yik . We fit a linear regression model:
E(yik |zik ,Tik) = z′ikγk + Tikθk , (2.1)
where γk is a (1 × q) coefficient vector representing the main effects of the covariates, and θk for the
treatment effect in a subtrial k is of our primary estimation interest. Within each subtrial
E(yik |zik ,Tik = 1) = z′ikγk + θk ,
E(yik |zik ,Tik = 0) = z′ikγk
leads to an estimator of the treatment effect over a placebo, denoted by (Tik) = θk .
A more accurate estimate for θk helps to support the decision as to whether a phase III trial of the
treatment should go ahead, and in which patient subgroup(s). Moreover, inferences based on evidence of
the basket trial can inform the design of a future trial, such as computing the sample size to sufficiently
power the trial. With respect to either continuing or halting the clinical evaluation, trial decisions per
subtrial can be framed as a decision between Go and No-go. Given a hypothesis for the treatment effect
per subtrial k:
H0 : θk ≤ 0 versus Ha : θk > 0,
investigators may base the trial decision on probabilistic inferences about θk to a threshold δU , which
represents the magnitude of improvement required to declare a clinical benefit of the new treatment,
in the Bayesian framework (Spiegelhalter and others, 1994). One example is to compute the posterior
probability of θk exceeding the threshold δU , in which it is not uncommon to pre-specify δU as a value
greater than 0. Here, we define a formal decision criterion: (i) a Go decision will be taken for subtrial k
if P(θk > δU ) > ζ , otherwise (ii) a No-go. This criterion refers to a quantity ζ ∈ [0, 1] as the level of
evidence that would be required for the new treatment to compellingly provide an improvement over the
control. Choices such as ζ = 0.90 may be appropriate. In what follows, we develop a novel Bayesian
model that leverages complementary data from the most consistent subtrials for estimating θk .
3. METHODS
Suppose the patient-level trial data can be modeled using a linear regression model in the form of (2.1),
and θk specific to a subtrial is a continuous location parameter. Letting xk denote the data from subtrial k
and π0k(θk) the initial vague (operational) prior, the information that subtrial k carries can be represented
by an operational posterior,
πk(θk |xk) ∝ L(xk |θk)π0k(θk), (3.1)
where L(·) denotes the likelihood function. We label the subtrial of our contemporary analysis interest
with k. For estimating each θk , information from a complementary subtrial k = k can be leveraged
through a commensurate predictive prior (CPP). Inspired byHobbsandothers (2011, 2012),we introduce a
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precision parameter, denoted by νkk , which parameterizes the consistency between θk and θk . Conditional
on the information commensurability, each predictive distribution for θk can be stipulated as
θk |θk , νkk ∼ N (θk , 1/ν2kk ), (3.2)
where θk follows the operational posterior in (3.1) and the unknown νkk determines the degree of
borrowing. This then leads to a CPP as
πCPP(θk , νkk |xk , θk) ∝ L(xk |θk)π0k(θk) × νkkφ((θk − θk)νkk ) × gk(νkk ), (3.3)
where φ(·) is the standard normal probability density function, and gk(νkk ) is the prior for νkk . If the
complementary subtrial k is consistent, with νkk 	 0, the marginal CPP for θk converges to the opera-
tional posterior πk(θk |xk) that is updated from π0k(θk), so that the complementary data xk will be largely
incorporated into subtrial k. Otherwise, with νkk ≈ 0, xk are discarded and the marginal CPP for θk
tends towards the operational prior for θk .
A spike-and-slab distribution (Mitchell and Beauchamp, 1988) has been found suitable as a prior for
the normal precision parameter (Hobbs and others, 2012, 2013). This is a discrete mixture prior with
two components, which can provide us a means for robust borrowing. Specifically, we define gk(νkk ) as
locally uniform between two limits, 0 ≤ B1 < B2, except some portion of probability mass concentrated
at a point, S > B2, such that
P(νkk < B1) = 0
P(νkk < u) = wkk · u − B1B2 − B1 , B1 ≤ u ≤ B2,
and P(νkk > B2) = P(νkk = S) = 1 − wkk ,
(3.4)
where wkk is the probability that νkk ∼ Unif(B1,B2). Given a subtrial k with sufficiently consistent
treatment effect, we expect strong borrowing from xk . This requires that the normal precision parameter
νkk in (3.3) takes a large value, which is possible when the “spike” prior has a large probability mass, that
is, when wkk is sufficiently small. Otherwise, xk is down-weighted by allocating more probability mass
to the “slab” prior. We interpret wkk as our prior opinion (on the probability scale) about the pairwise
subtrial incommensurability.
To determinewkk , we propose using a discrepancymeasure that quantifies the distributional divergence
between the posterior density distributions, πk(θk |xk) and πk (θk |xk ), arising from the same operational
prior. One viable option is the Hellinger distance (Dey and Birmiwal, 1994):
dH (πθk ,πθk) =
√√√√1
2
∫ ∞
−∞
(√
dπk (θk |xk )
dθ
−
√
dπk(θk |xk)
dθ
)2
dθ . (3.5)
Derivable from the Cauchy–Schwarz inequality, the computed Hellinger distance dφH (πθk ,πθk) will
strictly fall into the interval of [0, 1], which is convenient for characterizing the probability that treatment
effects of any two subtrials are regarded as dissimilar.We may then relate the “slab” prior probability wkk
with the computed Hellinger distance, simply by stipulating wkk = dH (πθk ,πθk). In an extreme case that
two subtrials are perfectly consistent, i.e., dH (πθk ,πθk) → 0, the whole probability mass will be concen-
trated at the “spike,” S. In turn, this will result in a notably small normal variance 1/ν2kk of the CPP in (3.3)
such that the complementary subtrial data xk can be fully incorporated. In addition, knowing the upper
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and lower bounds, which are 0 and 1 for the Hellinger distance, makes it easier to standardize a collection
of pairwise discrepancy measurements. This can help quantify the relative importance of all other subtrials
k = k to form a prior for θk in circumstances of K ≥ 3. More importantly, the Hellinger distance is
preferred over other distributional discrepancy measures, because of its desirable properties of symmetry
and invariance to any transformation, for example, logarithmic, exponential, or inverse of square root,
of both densities (Jeffreys, 1961). As a symmetric measure of discrepancy, dH (πθk ,πθk) = dH (πθk ,πθk ).
In a basket trial with K = 2 and no a priori assumption about which subtrial has stronger treatment
effect, using the Hellinger distance to define the spike-and-slab prior will result in the same magnitude
of down-weighting or leveraging subtrial data x1 to subtrial 2 and x2 to subtrial 1. Whilst the invariance
property ensures that the computed Hellinger distance dH (πθk ,πθk) truly reflects the discrepancy between
the treatment effect distributions in different patient subtrials, when the linear regression model (2.1) may
be parameterized in a different way, for example, with the treatment effect represented by the exponential
of θk . Given the invariance, we know that dH (πθk ,πθk) = dH (πexp(θk ),πexp(θk )).
For any θk , there exist (K − 1) complementary subtrials as the sources where the possible values can
be drawn upon. We now turn our attention to combining the (K − 1) CPPs for synthesizing information
from these complementary subtrials for basket trials with K ≥ 3. The CPPs for point-to-point borrowing
are robust in that inconsistent information from any subtrial k = k can be down-weighted through the
“slab” prior placed on each νkk , incorporating the use of pairwise Hellinger distance. If values of νkk are
appropriately specified, we may obtain (K − 1) predictive priors marginally on θk :
∫
πCPP(θk , νkk |xk , θk)dνkk ∝
∫
L(xk |θk)π0k(θk) × νkkφ((θk − θk)νkk )gk(νkk )dνkk , (3.6)
where each one separately may be represented as approximately a N (λk , ξ 2k ) distribution for ease of
notation. We further see θk as a weighted sum of (K − 1) hypothetical random variables:
θk =
K∑
k=1, k =k
pkk θ˜k , for k = 1, . . . ,K , (3.7)
where we suppose each θ˜k ∼ N (λk , ξ 2k ) and the weight vector pk = (p1k , p2k , . . . ), containing (K − 1)
elements, satisfies
∑
pk = 1. This further gives
θk |x(−k) ∼ N
⎛
⎝ K∑
k=1, k =k
pkkλk ,
K∑
k=1, k =k
p2kkξ
2
k
⎞
⎠ , (3.8)
in which x(−k) denotes the entire trial data excluding those from subtrial k. This allows for leveraging
information frommultiple sources. This marginal predictive prior, denoted byπMPP(θk |x(−k)), is updated
to the posterior with the subtrial data xk using Bayes’ Theorem:
πMPP(θk |xk , x(−k)) ∝ L(xk |θk ) × πMPP(θk |x(−k)), (3.9)
so as to inform decision making for subtrial k.
To allocate a sensible weight to each complementary subtrial, we expect pkk to take large values
(close to 1) if subtrials k and k are consistent. Specification of these weights pkk may be guided by the
Hellinger distance, dH (πθk ,πθk) (labeled as dkk for notation simplicity), which we use to measure the
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commensurability between subtrials k and k. For a basket trial with K subtrials, the Hellinger distances
can be organized as a K × K symmetric matrix:
⎛
⎜⎜⎜⎝
0 d12 · · · d1K
d21 0 · · · d2K
...
...
. . .
...
dK1 dK2 · · · 0
⎞
⎟⎟⎟⎠ ,
where each column k = 1, . . . ,K describes the pairwise distributional discrepancy between our target
parameter θk and a source parameter θk , for k = k. Hellinger distances contained in each column k
can be normalized into a series of weights pkk ∈ [0, 1]. For this, we will simply stipulate a decreasing
function of dkk as
pkk = exp(−dkk/s0)∑
k exp(−dkk/s0)
, (3.10)
where a pre-defined s0 governs how much influence the Hellinger distance has on the weight to be
computed. With a value of s0 	 dkk , nearly the same weight will be allocated irrespective of the pairwise
Hellinger distances that could be very different from each other. Whereas, with s0 → 0+, the weight
corresponding to a Hellinger distance close to 0 tends to be 1. In SectionA of the supplementary material
available at Biostatistics online, we illustrate properties of this transformation analytically in more details.
Weights converted from the pairwise Hellinger distances following (3.10) can then be assigned to each
θ˜k , as was stipulated in (3.7).
We would like to add one more note here. The stipulation of weights pkk summing to 1 does not
restrict the potential of full borrowing of information in situations, where all the (K − 1) complementary
subtrials are perfectly consistent with subtrial k. In such a scenario, the Hellinger distance dkk = 0,
suggesting that the CPPs marginally on θk , represented by N (λk , ξ 2k ), have identical mean and variance to
those of πk (θk |xk ). Moreover, equal weights, i.e., pkk = 1K−1 , will be allocated to the complementary
subtrials, k = k. Following (3.8), a predictive prior πMPP(θk |x(−k)) would be obtained with its mean
as λk and variance as 1K−1ξ
2
k . With the inclusion of xk , the posterior mean and variance become λk and
1
K ξ
2
k , respectively. This indicates all the complementary subtrial data x(−k) have been fully incorporated,
and our methodology converges to the approach of complete pooling in the case of perfect information
consistency.
4. SIMULATION STUDY
In this section, we illustrate applications of the proposed analysis methodology, and compare it with
alternative Bayesian models that may be used for analyzing basket trials through a simulation study. Our
trial examples are hypothetical, but can represent the situation of a phase II basket trial, for which the
analyses are performed to enable sharing of information. The main characteristics of the basket trials we
simulate are based on the motivating PBC and PD trial described in Section 2. For illustrative purposes,
we assume six subtrials instead of three, as typically a fairly large number of patient subgroups would be
examined; for example, Hyman and others (2015, 2018) report the results from basket trials with six and
nine subtrials, respectively.
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Table 1. Simulation scenarios with specification of the “true” treatment effect θk to
compare the Bayesian analysis models.The figure in bold indicates a 0 or low treatment
effect.
Subtrial k (Sample size, nk )
Scenario 1 (n1 = 10) 2 (n3 = 10) 3 (n2 = 14) 4 (n5 = 16) 5 (n4 = 20) 6 (n6 = 20)
1 0.49 0.67 0.54 0.43 0.79 0.35
2 0.35 0.37 0.80 1.30 1.38 0.40
3 0.29 0.77 0.68 0.75 0.33 0.30
4 0.59 1.17 1.02 0.95 0.13 0.75
5 0.45 0.45 0.45 0.45 0.45 0.45
6 0.30 0.30 0.30 0.30 0.30 0.30
7 0 0 0 0 0.37 0.37
8 0.33 0 0.82 0.90 0 0.83
9 0 0 0 0 0 0
4.1. Basic settings
We simulate basket trials with K = 6 subtrials of unequal sample sizes: nk ∈ {10, 10, 14, 16, 20, 20},
respectively. Treatment allocation to individual patients follows a block approach by subtrial, with exactly
half of the subtrial sample size to receive the treatment and the other half to placebo. We simulate two
covariates for each patient as zik1 ∼ N (6, 0.22) and zik2 ∼ N (4, 0.22), for i = 1, . . . , 90. In particular,
zik1 is assumed to be the baseline measurement of the clinical endpoint at the time of randomization. We
generate the trial data from a linear regression: for i = 1, . . . , 90, k = 1, . . . , 6,
yik ∼ N (ηik , σ 2) i.i.d.
ηik = γ0k + zik1γ1k + zik2γ2k + Tikθk ,
(4.1)
where we set the “true” parameter values for the intercept and main effects of baseline covariates to
γ0k = 5, γ1k = 3, and γ2k = 1.3, and the inter-patient standard deviation σ = 0.4 to generate the
data. Basket trials are simulated under nine scenarios (listed in Table 1), which feature varying treatment
effect sizes θk and different degrees of heterogeneity across subtrials. All sets of the “true” values of θk
are realizations from distinct multivariate normal distributions: we stipulated a high pairwise correlation
coefficient (0.8) for θk of the consistent subtrials and a low pairwise correlation coefficient (0.1) between
θk of an extreme subtrial and of one else from the rest. In particular, scenarios 7 and 8 can be seen as
“mixed null” scenarios, and scenario 9 is a “global null”.
When fitting the Bayesian analysis models, we consider random effects for γ0k , γ1k , and γ2k :
γ0k = χ0 + 20 , γ1k = χ1 + 21 , and γ2k = χ2 + 22 ,
setting an uninformative normal prior N (0, 52) on each χj and a half-normal prior HN (z) on each j, for
j = 0, 1, 2. Here, HN (z) is defined as a N (0, z2), truncated to cover the interval (0,∞). The use of a
half-normal prior is consistent with the recommendation by Cunanan and others (2019).We stipulate j ∈
HN (1), of which the prior and 95% credible interval are 0.674 and (0.031, 2.241), to permit very limited
information borrowing across subtrials for estimating γjk , j = 0, 1, 2, k = 1, . . . , 6. In the following,
we describe additional specifications to implement the Bayesian models that estimate θk with or without
information leveraged from other subtrials.
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To implement our methodology for estimating θk , we choose setting B1 = 0.01, B2 = 1, and S = 100
for the spike-and-slab prior on each νkk . The “slab” prior is very uninformative and is sufficient to fully
discard the entire information from an external subtrial k; the “spike” prior is specified so that the proposed
methodology can be reduced to complete pooling in situations of perfect information commensurability.
Justification of choosing this spike-and-slab prior is provided in Section B of the supplementary material
available atBiostatistics online.An initial vague priorπ0k(θk) is used for θk , k = 1, . . . , 6; we useN (0, 102)
such that the 95% prior credible interval is (−19.560, 19.560), covering a wide range of possible θk . To
yield a large (small) weight pkk corresponding to a small (large)Hellinger distance, we let s0 = 0.15 for the
transformation. Nevertheless, we study how different stipulations of s0 may impact on the identification of
the most consistent subtrial(s) in Section C of the supplementary material available at Biostatistics online,
exploring s0 = 0.25, 0.35, 0.45 in addition. We are interested in comparing the proposed methodology
with
(1) Standard hierarchical model (HM) that assumes fully exchangeable parameters: θk |μ,τ ∼ N (μ, τ 2)
with μ ∼ N (0, 102) and τ ∼ HN (0.125). The median and 95% credible interval of HN (0.125) are
0.084 and (0.004, 0.280), respectively.
(2) Bayesian model with no borrowing of information. Trial data are stratified by subtrials for stand-
alone analyses, setting each θk ∼ N (0, 102). Random effects for γ0k , γ1k , and γ2k therefore cannot
be estimated; we then place a N (0, 52) prior on each.
(3) EXNEX model by Neuenschwander and others (2016), with equal prior probabilities of exchange-
ability (EX) and non-exchangeability (NEX). The EX distribution has the same parameter
configuration as what was stipulated for the standard HM above, and the six NEX distributions
are all set to be N (0, 102).
Comparison is in terms of the precision of their posterior point estimates,more specifically, the posterior
means, for θk that could be measured by an analog of bias and mean squared error (MSE):
Bias(θk) ≈ 1
M
M∑
m=1
θ¯mk − θk ,
MSE(θk) ≈ 1
M
M∑
m=1
(θ¯mk − θk)2,
where M is the total number of replicates in the simulation study, and θ¯mk denote the posterior means of
θk for the mth simulated basket trial. These metrics will be reported by subtrial. We also compare these
Bayesian analysis models with respect to the trial operating characteristics, such as the subtrial-wise error
rates. Corresponding to the frequentist type I error rate and statistical power, we will report proportions
of the simulated trials with
• an erroneous Go decision in a subtrial where the “true” θk = 0, and
• a correct Go decision in a subtrial where the “true” θk > 0,
respectively. An overall (analog of) type I error rate, computed as proportion of trials with an erroneous
Go decision made for at least one subtrial, will also be reported for scenarios with null θk ’s. In particular,
a Go will be allocated if P(θk > δU ) > 0.975. Trial operating characteristics will be evaluated setting
δU = 0.25, 0.30. We are especially interested in Scenarios 7–9, the mixed or global null scenarios, to
report the (analog of) type I error rate by both subtrial and overall.
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Fig. 1. Bias and mean squared error of the posterior estimators for θk based on the Bayesian models.
Results are summarized by averaging across 10 000 replicates of the basket trial. The Bayesian anal-
ysis models are fitted in R version 3.4.4 using the R2OpenBUGS package based on two parallel chains,
with each running the Gibbs sampler for 10 000 iterations that follow a burn-in of 3000 iterations. Open-
BUGS code, together with R functions, to implement each of the Bayesian analysis models is available
at https://github.com/BasketTrials/Bayesian-analysis-models.
4.2. Results
Figure 1 compares the performance of the posterior estimators yielded by the Bayesian models. It shows
that the proposed methodology produces smaller bias and MSE compared with the standard HM and
EXNEX, across nearly all scenarios. Point estimators based on the standard HM and EXNEX work well
in scenarios 5, 6, and 9 as the small-to-moderate variability between θks can be addressed by setting
τ ∼ HN (0.125). The proposed analysis methodology, in contrast, distinguishes the heterogeneity more
sensitively. Much smaller bias and MSE are yielded when estimating θk for basket trials with divergent
treatment effects across subtrials; see, for example, scenario 2. In situations where information from other
subtrials should be largely discounted, referring to scenarios 7 and 8, our methodology generates compara-
tively similar bias to the no borrowing approach but with a smaller MSE. This is because information from
subtrials with a non-zero treatment effect, can be largely discounted to formulate the marginal predictive
prior for e.g., θ2 in scenario 8.
We have also compared the Bayesian analysis models in terms of the average width of the posterior
credible intervals for θk . In contrast to the alternative Bayesian models, the proposed methodology yields
posterior estimates with narrower credible intervals when there is at least one consistent complementary
subtrial; see Figure S1 of the supplementary material available at Biostatistics online. When using the
proposed analysis methodology for borrowing of information, investigators may be interested in the
weight eventually allocated to each external subtrial for obtaining the marginal predictive prior. In Figures
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Table 2. Comparison of the Bayesian analysis models with respect to the analogue of type
I error rate: null hypothesis is erroneously rejected under scenarios of any θk = 0, setting
δU = 0.25 and ζ = 0.975.
Subtrial
1 2 3 4 5 6 Overall
Scenario 7 Standard HM 0.0000 0.0000 0.0000 0.0000 — — 0.0000
No borrowing 0.0036 0.0077 0.0056 0.0100 — — 0.0269
EXNEX 0.0001 0.0003 0.0002 0.0000 — — 0.0006
Proposed approach 0.0073 0.0089 0.0002 0.0002 — — 0.0166
Scenario 8 Standard HM — 0.0155 — — 0.0080 — 0.0207
No borrowing — 0.0077 — — 0.0008 — 0.0085
EXNEX — 0.0195 — — 0.0056 — 0.0251
Proposed approach — 0.0155 — — 0.0017 — 0.0172
Scenario 9 Standard HM 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
No borrowing 0.0036 0.0077 0.0056 0.0100 0.0008 0.0006 0.0283
EXNEX 0.0000 0.0001 0.0000 0.0000 0.0000 0.0000 0.0001
Proposed approach 0.0014 0.0028 0.0000 0.0000 0.0002 0.0020 0.0064
Overall: the proportion of trials with erroneous Go decision for at least one subtrial.
S3 and S4 of the supplementary material available at Biostatistics online, we comment with regards to
scenarios 4 (divergent θk ) and 5 (consistent θk ) on the weight allocation based on the assessed pairwise
commensurability, and illustrate how the pre-specified value of s0 would impact the sensitivity of the
proposed methodology to identify the most commensurate subtrial(s).
Table 2 quantifies the impact of using different Bayesian models on the error rate control under the
null hypothesis. Here, we report the (analog of) type I error rate for scenarios involving at least one
subtrial with θk = 0, setting δU = 0.25. Comparisons where we set δU = 0.30 are given in Table S1 of the
supplementary material available at Biostatistics online. For scenario 9 (global null), all the four Bayesian
analysis models control the error rate well following the decision criterion. Nevertheless, the approaches
that enable borrowing of information, i.e., standard HM, EXNEX, and the proposed methodology, have
resulted in smaller type I error rates, compared with the approach of no borrowing, since incorporating
consistent information from other subtrials reassures that making a Go decision is not justified. Our
approach produces slightly higher error rates than standard HM and EXNEX, as for some simulated trials
information from subtrials with a similar low treatment effect may be shared (but not with those of a null
θk ’s), leading to a higher chance to reject the null hypothesis. In scenario 8 where some subtrials have
large treatment effects, we observe a higher error rate when using standard HM and EXNEX approaches,
compared with the proposed approach. We note that a difference in the sample sizes of subtrials 2 and 4
or 5 (for all scenarios) leads to disparate magnitudes of the error rate using the same approach in the same
null scenario: those for subtrial 2 are regularly larger than subtrial 4 or 5. More explicitly, when reacting
to a data conflict, a larger sample size of subtrial 4 or 5 provides more evidence to evaluate the plausibility
of down-weighting; estimation of θ4 or θ5 thus has increased chances to avoid being overwhelmed by the
complementary information.
What may also be interesting to investigators is the potential increase in statistical power to demonstrate
the treatment effect, by incorporating information from complementary subtrials. Figure 2 visualizes the
comparison of the Bayesian analysis models in terms of correctly declaring a clinical benefit in subtrial k ,
setting δU = 0.25; see Figure S5 of supplementary material available at Biostatistics online that visualizes
D
ow
nloaded from
 https://academ
ic.oup.com
/biostatistics/advance-article-abstract/doi/10.1093/biostatistics/kxaa019/5831921 by U
niversity of N
ew
castle user on 27 M
ay 2020
12 H. ZHENG AND J. M. S. WASON
Scenario 5 Scenario 6 Scenario 7 Scenario 8
Scenario 1 Scenario 2 Scenario 3 Scenario 4
1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6
0
20
40
60
80
100
0
20
40
60
80
100
Subtrial
Pr
op
or
tio
n 
of
 tr
ia
ls
 w
ith
 a
 c
or
re
ct
 G
o 
un
de
rH
a
 
(%
)
Standard HM No borrowing EXNEX Proposed approach
Fig. 2. Comparison of the Bayesian analysis models with respect to the analog of statistical power: null hypothesis
is correctly rejected in the presence of a treatment effect per subtrial, setting δU = 0.25 and ζ = 0.975.
the comparison setting δU = 0.30.Across nearly all subtrials of the simulated basket trials in scenarios 1–
5, the Bayesian approaches of borrowing show substantial advantages over the approach of no borrowing.
When comparing between the Bayesian approaches of borrowing, we check how the chance would be
for a subtrial with comparatively low treatment effect to be concluded with a correct Go decision, in
the presence of consistent subtrials. Looking at scenarios 3, for example, our approach leads to higher
statistical power for subtrials 2 and 6 compared with other Bayesian models.
Scenarios 5 and 6 represent situations where all subtrials are commensurate, but the former has a
larger treatment effect size. Given our criterion that P(θk > 0.25) > 0.975 for a Go decision, scenario
6 with all θk = 0.30 is particularly a hard scenario to allocate a Go. Compared with the approaches
that enable borrowing, using the approach of no borrowing results in subtrials 3 and 4 having a slightly
higher probability of correct Go decision. However, this does not mean the no borrowing approach is
superior, since standard HM and EXNEX produce estimates of θk with a similar level of bias, but much
smaller posterior variances than the approach of no borrowing. These results are observed from Figure 1
and Figure S2 of the supplementary material available at Biostatistics online. More informative posterior
distributions for θk nevertheless do not necessarily mean a higher interval probability of θk > δU : it is
possible that diffuse posteriors for θk obtained from the approach of no borrowing has comparable or
even higher chances to exceed the level γ = 0.975. When the consistent “true” θks increase from 0.30
(scenario 6) to 0.45 (scenario 5), we begin to observe the efficiency gains by using Bayesian models that
permit borrowing of information than no borrowing. The proposed methodology appears to present a
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larger absolute gain in power compared with the alternative models, although we note that the absolute
gain in power can be a misleading metric due to the non-linear shape of the power curve.
In scenario 7, due to the prior specification of τ ∼ HN (0.125) being incapable of accounting for
the variability across subtrials, both standard HM and EXNEX shrink θ5 and θ6 excessively towards
the mean effect across subgroups. This in turn dilutes the treatment effect in corresponding subtrials.
Consequently, it seems better to implement the approach of no borrowing for possibility of declaring a
positive treatment effect. Our approach presents slightly higher power than the no borrowing approach
as there is some consistent information to be incorporated from a complementary subtrial. In scenario
8, our approach performs similarly to the alternatives, but slightly better for subtrial 6 due to leveraging
consistent information.
We note this simulation study does not consider cases of basket trials involving rare disease subgroups,
where certain subtrials can have a much smaller sample size than others. We present several hypothetical
data examples in Section D of the supplementary material available at Biostatistics online to comment on
the sensitivity to the difference in subtrial sample sizes.
5. DISCUSSION
The paradigm shift towards precision medicine opens new avenues for novel trial designs and analysis
methodologies to deliver more tailored healthcare to patients. Basket trials emerge as a new class of
efficient approaches to oncology drug development in the era of precision medicine, offering a framework
to evaluate the treatment effect together with its heterogeneity in various patient subgroups. In this article,
wehave extended the key ideas of a basket trial approach to disease areas outside of oncology, andproposed
a newBayesianmodel to enable borrowing of information from themost commensurate subtrial(s) without
requiring a priori clustering of similar subgroups. By including an information discrepancy measure, it
can discern the degree of borrowing from complementary subtrials. In particular, the Hellinger distance
plays a dual role in our methodology: (i) it gauges the maximum amount of information that could be
leveraged from a specific subtrial k = k to estimate θk ; (ii) when there are K ≥ 3 subtrials, it determines
the weight allocation to reflect the relative importance for appropriate borrowing of information.
TheBayesian analysismethodology in Section 3 has been developed assuming the basket trial generates
continuous response data. However, it could be easily generalized to analyze other types of data that can
be fitted using a generalized linear model for non-Gaussian error distributions. For example, it would be
readily applicable to analyzing phase II basket trials that use binary endpoints: after fitting the patient-
level data per subtrial with a logistic regression model, our approach may be considered to stipulate
commensurate predictive priors, informed by the pairwise Hellinger distance, for the subtrial-specific
treatment effect parameters to permit borrowing of information from the most consistent subtrial(s). For
down-weighting in cases of a data conflict suggested by the Hellinger distance, we did not delve into
calibration of the “slab” prior but simply used a very uninformative uniform distribution, which ensures
data from an inconsistent subtrial can be discarded. When using the proposed methodology in practice,
we recommend specifying the spike-and-slab prior based on some preliminary knowledge about the
magnitude of variances of θk . Specification of the “slab” prior may particularly deserve future research to
exploit the advantage of the proposed methodology. We refer to Mutsvari and others (2016) as a relevant
investigation, which focuses on choosing the diffuse component of a mixture prior for robust inferences.
We also note that the exploration may be closely linked with the users’ stipulation of the prior probability
weight, which is based upon the Hellinger distance, to be attributed to the “slab” prior.
In our simulation study, we have considered imbalance subtrial sizes. Simulation results show that
our methodology can down-weight inconsistent information from a subtrial that has larger sample sizes.
For illustrative purposes, we have supposed equal randomization ratio between treatment groups within
a subtrial. Investigators can pragmatically determine the randomization ratio as well as the subtrial-wise
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sample size for a basket trial that may base decision making on our analysis methodology. Potentially,
more dosage groups of the same treatment in each subtrial can be considered. Also, many have shown
a great interest in sequential basket trials (Simon and others, 2016; Cunanan and others, 2017; Hobbs
and Landin, 2018) with interim look(s) incorporated for the possibility of, say, terminating enrollment
of patients in ineffective subgroups. We note that the proposed Bayesian approach can be implemented
with any number of analyses following a flexible timescale for interim decision making. There is no
requirement of a minimum sample size per subtrial to carry out an interim look, due to the use of an initial
operational prior π0k(θk) for computing the pairwise Hellinger distance. However, an inflation of type I
error rate arising from such repeated significance tests would occur.
Throughout, we have restricted our focus onto basket trials, where the subtrials use the same endpoint
across patient subgroups. In many disease areas, multiple endpoints (FDA, 2017) may often arise, as it
could involve various dimensions to conclude on the clinical benefit. One common situation is to continue
monitoring toxicity in addition to the assessment of efficacy (Bryant and Day, 1995; Tournoux and others,
2007).With regards to this, our approach could be extended in severalways. For instance, in caseswhere the
set of multiple endpoints remain the same across subgroups, it would be straightforward to establish a joint
probability model and derive the pairwise Hellinger distance between multivariate probability densities
(Pardo, 2005). Suitable alternatives include separating the discussion about borrowing of information by
endpoint. A unified utility function may then be adopted for trial decision making based on evidence on
multiple endpoints. In another more complex setting where the efficacy endpoint, for example, could be
distinct but correlated across subgroups, one might need to translate the subtrial data onto a common
scale in order to adapt the present approach. Ideas could be drawn from Zheng and others (2020), where
incorporation of supplementary data recorded on a different measurement scale has been discussed in the
context of phase I clinical trials.
6. SOFTWARE
Software in the form of OpenBUGS code together with R functions is available on GitHub
(https://github.com/BasketTrials/Bayesian-analysis-models).
SUPPLEMENTARY MATERIAL
Supplementary material is available at http://biostatistics.oxfordjournals.org.
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